Pharmaceutical

Regeneron to acquire rights for Hansoh’s HS-20094 therapy

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094.

Jun 3, 2025 - 06:00
Regeneron to acquire rights for Hansoh’s HS-20094 therapy
Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094.
Read the original article

Tags:

Previous Article

Biosensors Revolutionize Gastrointestinal Tumor Detection

Next Article

ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation

STAT+: ‘It was my call’: Stanford president defends dec...

Apr 11, 2023

Opinion: How the Wegovy shortage is making life impossible for my patients — and for me

Opinion: How the Wegovy shortage is making life impossi...

Sep 16, 2023

Tacalyx extends seed funding round to raise over €14m

Tacalyx extends seed funding round to raise over €14m

Jun 12, 2024